Related Experiment Video

Updated: May 17, 2026

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

Frontiers of rapid itch relief: a review of methylprednisolone aceponate

L García Ponte1, U Ebert

  • 1Dermatology, Bayer Health Care Consumer Care, Madrid, Spain. lorenzo.garcia.ponte@bayer.com

Journal of the European Academy of Dermatology and Venereology : JEADV
|October 17, 2012
PubMed

Insights

Methylprednisolone aceponate (MPA) offers rapid itch relief for childhood atopic dermatitis (AD) in infants and children. This potent topical corticosteroid provides an improved safety profile and convenient once-daily application for effective AD management.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pharmacology

Background:

  • Childhood atopic dermatitis (AD) management requires therapies with proven safety, tolerability, and anti-pruritic effects, especially in infants and young children.
  • The speed of itch relief is a critical factor in selecting treatments for pediatric AD.

Purpose of the Study:

  • To evaluate methylprednisolone aceponate (MPA), a fourth-generation topical corticosteroid (TC), for its efficacy and safety in managing atopic dermatitis (AD) in pediatric patients.
  • To highlight MPA's fast-acting anti-pruritic benefits and therapeutic index in children and infants.

Main Methods:

  • Review of evidence-based data on the use of MPA in pediatric populations with AD.
  • Assessment of MPA's anti-inflammatory and anti-pruritic properties, safety, tolerability, and application frequency.

Main Results:

  • MPA demonstrates a fast and effective itch relief profile in infants and children (from 2 months of age) with AD.
  • MPA exhibits a significantly improved therapeutic index compared to traditional TCs, offering increased potency with fewer side effects.
  • Once-daily application and versatile formulations enhance MPA's suitability for pediatric AD treatment.

Conclusions:

  • Methylprednisolone aceponate (MPA) is an optimal choice for both acute and maintenance therapy in pediatric patients experiencing AD-related pruritus.
  • Its favorable safety profile, rapid efficacy, and convenient dosing make MPA a valuable therapeutic option for childhood atopic dermatitis.

Related Concept Videos

Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Local Anesthetics: Common Agents and Their Applications01:23

Local Anesthetics: Common Agents and Their Applications

Local anesthetics (LAs) are commonly used for various applications in medical and dental procedures. Some of the common agents used are cocaine, lidocaine, and bupivacaine.
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...